Loading...
Market
Story
Eli Lilly Seeks FDA Approval for Zepbound to Treat Sleep Apnea, Resolving Symptoms in Up to 52% of Patients
Jun 21, 2024, 08:14 PM
Eli Lilly has formally requested FDA approval to expand the use of its weight-loss drug Zepbound to treat obstructive sleep apnea (OSA). The company announced that Zepbound, also known as tirzepatide, has shown significant efficacy in resolving moderate to severe OSA in up to 52% of patients in two late-stage clinical trials. In addition to improving sleep apnea symptoms, the drug also improved body weight, the apnea-hypopnea index, hypoxic burden, hsCRP concentration, and systolic blood pressure. Zepbound helped at least 43% of patients with OSA and obesity resolve symptoms. Up to 51.5% of participants met the criteria for disease resolution. Eli Lilly anticipates a decision from the FDA by the end of the year.
View original story
Similar markets
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Improves blood pressure only • 33%
Improves blood pressure and one other measure • 33%
Improves blood pressure and multiple other measures • 33%
0-25% reduction • 25%
26-50% reduction • 25%
51-75% reduction • 25%
76-100% reduction • 25%
Yes • 50%
No • 50%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
Cost decreases significantly • 25%
Cost decreases slightly • 25%
Cost remains the same • 25%
Cost increases • 25%
No additional studies • 33%
1-2 additional studies • 33%
3 or more additional studies • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%